Atypical antipsychotics and dopamine D1 receptor agonism: an in vivo experimental study using core temperature measurements in the rat

2000 ◽  
Vol 10 ◽  
pp. 308
Author(s):  
S. Ahlenius ◽  
S. Oerther
Synapse ◽  
2008 ◽  
Vol 62 (7) ◽  
pp. 534-543 ◽  
Author(s):  
H.Y. Lee ◽  
N. Naha ◽  
S.P. Li ◽  
M.J. Jo ◽  
M.L. Naseer ◽  
...  

2019 ◽  
Vol 10 (9) ◽  
pp. 4160-4182 ◽  
Author(s):  
Michael L. Martini ◽  
Caroline Ray ◽  
Xufen Yu ◽  
Jing Liu ◽  
Vladimir M. Pogorelov ◽  
...  

2000 ◽  
Vol 129 (5) ◽  
pp. 853-858 ◽  
Author(s):  
Sylvia S W Ng ◽  
Catherine C Y Pang

2020 ◽  
Author(s):  
Stephanie C. Gantz ◽  
Maria M. Ortiz ◽  
Andrew J. Belilos ◽  
Khaled Moussawi

SUMMARYUltrapotent chemogenetics, including the chloride-permeable inhibitory PSAM4-GlyR receptor, were recently proposed as a powerful strategy to selectively control neuronal activity in awake, behaving animals. We aimed to validate the inhibitory function of PSAM4-GlyR in dopamine D1 receptor-expressing medium spiny neurons (D1-MSNs) in the ventral striatum. Activation of PSAM4-GlyR with the uPSEM792 ligand enhanced rather than suppressed the activity of D1-MSNs in vivo as indicated by increased c-fos expression in D1-MSNs. Whole-cell recordings in mouse brain slices showed that activation of PSAM4-GlyR did not inhibit firing of action potentials in D1-MSNs. Activation of PSAM4-GlyR depolarized D1-MSNs, attenuated GABAergic inhibition, and shifted the reversal potential of PSAM4-GlyR current to more depolarized potentials, perpetuating the depolarizing effect of receptor activation. The data show that ‘inhibitory’ PSAM4-GlyR chemogenetics may actually activate certain cell types, and highlight the pitfalls of utilizing chloride conductances to inhibit neurons.


2020 ◽  
Author(s):  
Jace Jones-Tabah ◽  
Hanan Mohammad ◽  
Shadi Hadj-Youssef ◽  
Lucy Kim ◽  
Ryan D. Martin ◽  
...  

AbstractLike many G protein-coupled receptors (GPCRs), the signalling pathways regulated by the dopamine D1 receptor (D1R) are dynamic, cell-type specific, and can change in response to disease or drug exposures. In striatal neurons, the D1R activates cAMP/protein kinase A (PKA) signalling. However, in Parkinson’s disease (PD), alterations in this pathway lead to activation of extracellular regulated kinases (ERK1/2), contributing to L-DOPA-induced dyskinesia (LID). In order to detect D1R activation in vivo and to study the progressive dysregulation of D1R signalling in PD and LID, we developed ratiometric fiber-photometry with Förster resonance energy transfer (FRET) biosensors and optically detected PKA and ERK1/2 signalling in freely moving rats. We show that in Parkinsonian animals, D1R signalling through PKA and ERK1/2 is sensitized, but that following chronic treatment with L-DOPA, these pathways become partially desensitized while concurrently D1R activation leads to greater induction of dyskinesia.


2004 ◽  
Vol 90 (4) ◽  
pp. 865-873 ◽  
Author(s):  
Mella Adlersberg ◽  
Shu-chi Hsiung ◽  
Sara B. Glickstein ◽  
Kuo-peing Liu ◽  
Hadassah Tamir ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document